Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study

• Published in: Frontiers in immunology Vol. 13; p. 1049908
• Main Authors: Hu, Yi, Xu, Xin, Liu, Xiao-Shun, He, Cong, Ouyang, Yao-Bin, Li, Nian-Shuang, Xie, Chuan, Peng, Chao, Zhu, Zhen-Hua, Xie, Yong, Shu, Xu, Zhu, Yin, Graham, David Y., Lu, Nong-Hua
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 13.01.2023
• Subjects: amoxicillin; Amoxicillin - adverse effects; Anti-Bacterial Agents - adverse effects; Clarithromycin - therapeutic use; dual therapy; efficacy; Helicobacter Infections - drug therapy; Helicobacter pylori; Humans; Immunology; Prospective Studies; Proton Pump Inhibitors - therapeutic use; vonoprazan; amoxicillin; Helicobacter pylori; vonoprazan; efficacy; dual therapy

We previously reported that vonoprazan-amoxicillin (VA) dual therapy for 7 or 10 days is not satisfactorily efficacious for ( ) eradication. We aimed to explore the efficacy of VA dual therapy for 14 days as a first-line treatment for infection. This was a single center, prospective, open-labeled, r...